Evidence map›Paper›PMID 33202736›Full record

ArticleCancers2020

Effects of the Minimal Extrathyroidal Extension on Early Response Rates after (Adjuvant) Initial Radioactive Iodine Therapy in PTC Patients.

Freba Ahmaddy, Vera Wenter, Harun Ilhan, Daniel Wacker, Marcus Unterrainer, Thomas Knösel, Peter Bartenstein, Christine Spitzweg, Sebastian Lehner, Andrei Todica

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. The Diagnostic Usefulness ofDiagnostics (Basel, Switzerland) · 2021
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Freba AhmaddyDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
Vera WenterDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
Harun IlhanDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
Daniel WackerDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
Marcus UnterrainerDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
Thomas KnöselInstitute of Pathology, Ludwig-Maximilians-University of Munich, 81377 Munich, Germany.
Peter BartensteinDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
Christine SpitzwegDepartment of Internal Medicine IV, University Hospital, LMU Munich, 81377 Munich, Germany.
Sebastian LehnerDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
Andrei TodicaDepartment of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0003-1504-6565
LMU Klinikum · DELudwig-Maximilians-Universität München · DE

Funding

Kuhbier-Langewiesche foundation, Bavarian Equal Opportunities Sponsorship (BGF) -
6 · The paper itself

Abstract

backgroundExtrathyroidal extension of differentiated thyroid cancer is a poor outcome factor but seems to be less significant in minimal extrathyroidal extension (mETE). However, the impact of mETE on response rate after (adjuvant) initial radioactive iodine (RAI) therapy remains unclear. We therefore compared response rates of patients with classical and follicular variants of papillary thyroid cancer (PTC) according to the updated eighth tumor-node-metastasis (TNM) classification to a control group.

methods455 patients with T3 (primary tumor > 4 cm) PTC according to the seventh classification who underwent total thyroidectomy followed by RAI therapy were screened. Patients formerly classified as T3 PTC solely due to mETE were reclassified into patients with T1 (primary tumor ≤ 2 cm) or T2 (primary tumor > 2 cm but ≤ 4 cm) +mETE and compared to a control group of T1/T2 -mETE PTC patients.

results138/455 patients were reclassified as T1/2 +mETE and compared to 317/455 T1/T2 -mETE control patients. At initial presentation, +mETE patients showed significantly higher rates of cervical lymph node metastases (

conclusionResponse rates after RAI therapy were comparable in PTC patients irrespective of mETE but with higher rates of lymph node metastases.

Indexed as

differentiated thyroid cancerminimal extrathyroidal extensionpapillary thyroid cancerradioactive iodine therapy

Identifiers

PMID33202736
PMCPMC7696574
OpenAlexW3106308709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.